

Antibody titers decline 3-month post-vaccination with BNT612b2

Julien Favresse (✉ j.favresse@labstluc.be)

Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium and Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium.

Jean-Louis Bayart

Department of Laboratory Medicine, Clinique St-Pierre, Ottignies, Belgium.

François Mullier

Department of Laboratory Medicine, Université catholique de Louvain, CHU UCL Namur, Yvoir, Namur, Belgium.

Marc Elsen

Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium.

Christine Eucher

Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium.

Sandrine Van Eechhoudt

Department of Internal Medicine, Clinique St-Luc Bouge, Namur, Belgium.

Tatiana Roy

Department of Laboratory Medicine, Clinique St-Pierre, Ottignies, Belgium.

Gregoire Wieers

Department of Internal Medicine, Clinique St-Pierre, Ottignies, Belgium.

Christine Laurent

Department of Internal Medicine, Université catholique de Louvain, CHU UCL Namur, Yvoir, Namur, Belgium.

Jean-Michel Dogné

Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium.

Mélanie Closset

Department of Laboratory Medicine, Université catholique de Louvain, CHU UCL Namur, Yvoir, Namur, Belgium.

Jonathan Douxfils

Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium and Qualiblood sa, Namur, Belgium.

Keywords: COVID-19, SARS-CoV-2, mRNA vaccine, BNT162b2, antibody response, kinetics

Posted Date: June 1st, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-574216/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Antibody titers decline 3-month post-vaccination with BNT612b2

Julien Favresse^{1,2}, Jean-Louis Bayart³, François Mullier⁴, Marc Elsen¹, Christine Eucher¹, Sandrine Van Eechhoudt⁵, Tatiana Roy³, Gregoire Wieers⁶, Christine Laurent⁷, Jean-Michel Dogné², Mélanie Closset⁴, Jonathan Douxfils^{2,8}

¹*Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium.*

²*Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium.*

³*Department of Laboratory Medicine, Clinique St-Pierre, Ottignies, Belgium.*

⁴*Department of Laboratory Medicine, Université catholique de Louvain, CHU UCL Namur, Yvoir, Namur, Belgium.*

⁵*Department of Internal Medicine, Clinique St-Luc Bouge, Namur, Belgium*

⁶*Department of Internal Medicine, Clinique St-Pierre, Ottignies, Belgium.*

⁷*Department of Internal Medicine, Université catholique de Louvain, CHU UCL Namur, Yvoir, Namur, Belgium.*

⁸*Qualiblood sa, Namur, Belgium.*

***Correspondence:**

Julien Favresse
Department of Pharmacy,
University of Namur
B-5000 Namur, Belgium
Phone +32 81 72 43 91
Email: j.favresse@labstluc.be

Type of article: Brief article.

Running title: Antibody kinetics in vaccinated subjects (BNT162b2).

Keywords: COVID-19, SARS-CoV-2, mRNA vaccine, BNT162b2, antibody response, kinetics.

Words (manuscript): 1,282 (excluding references, figures/tables, and legends).

Words (abstract): 249

Number of authors: 12

Number of references: 12

Number of tables: 1

Number of figures: 1

Conflict of interest Disclosures: The authors have nothing to disclose.

Acknowledgment: We thank Roche Diagnostics for providing the kits for the evaluation.

Abstract

Introduction: Several studies reported on the humoral response in subjects having received the BNT162b2 mRNA COVID-19 vaccine. However, data on the kinetics of antibodies 3 months post-vaccination are currently lacking and are important to drive the future vaccination strategy.

Methods: The CRO-VAX HCP study is an ongoing multicenter, prospective and interventional study designed to assess the antibody response in a population of healthcare professionals who had received two doses of the BNT162b2 mRNA COVID-19 vaccine. Two-hundred individuals underwent a blood drawn within 2 days before the first vaccine dose. One-hundred and forty-two persons (71%) were categorized as seronegative at baseline while 58 (29%) were seropositive. Samples were then collected after 14, 28, 42, 56, and 90 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time points.

Results: Using a one-compartment kinetics model, the time to maximum concentration was estimated at 36 ± 3 days after the first dose and the estimated half-life of antibodies was 55 days (95% CI: 37-107 days) in seronegative participants. In seropositive participants, the time to maximum concentration was estimated at 24 ± 4 days and the estimated half-life was 80 days (95% CI: 46-303 days). The antibody response was higher in seropositive compared to seronegative participants.

Conclusion: In both seropositive and seronegative subjects, a significant antibody decline was observed at 3 months compared to the peak response. Nevertheless, the humoral response remained robust in all participants.

Introduction

The efficacy and safety of the two-dose regimen of BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech, Mainz, Germany) has been proved and led to its approval by several regulatory authorities in late December 2020.¹ Several studies have reported on the humoral response in vaccinated subjects but the results were only available after one administration of the vaccine and if the response after the second dose was evaluated, the follow-up of the participants was limited, i.e. below 3 months.²⁻⁶ Therefore, a longer follow-up period is needed to assess the antibody kinetics in individuals after a two-dose regimen of BNT162b2. These data are important, especially since the question about a third dose has been raised by the pharmaceutical industries which will led to important societal, logistical and economical consequences.

Material and methods

The CRO-VAX HCP study is an ongoing multicenter, prospective and interventional study designed to assess the antibody response in a population of healthcare professionals having received two doses of the BNT162b2 mRNA COVID-19 vaccine (Comirnaty®), as previously described in details.³ All participants provided informed consent prior to collection of data and specimen. The study was approved by a central ethical committee (approval number: 2020-006149-21). Participants received the first vaccine dose from January 18, 2021, to February 17, 2021. The second dose was administered 21 days after the first one. All volunteers underwent a blood drawn within 2 days before the first vaccine dose. Samples were then collected after 14, 28, 42, 56, and 90 days. Blood samplings performed earlier or later compared to the expected blood times collection were allowed (10% variation; i.e. 90 days \pm 4.5 days). In this interim report, data from a total of 200 participants were available after three months.

Antibodies against the SARS-CoV-2 nucleocapsid (anti-NCP; Elecsys Anti-SARS-CoV-2 NCP qualitative ECLIA, Roche Diagnostics, Machelen, Belgium) and the receptor binding domain of the S1 subunit of the spike protein (anti-S; Elecsys anti-SARS-CoV-2 spike quantitative ECLIA, Roche Diagnostics) were measured at each time point. Results above 0.8 or 0.165 for anti-S and anti-NCP antibodies were considered positives, according to previous data.³

Means and 95% confidence intervals (95% CI) were used to describe the data. The between group difference of antibody titers were tested using a Tukey multiple comparison test. A one-compartment modeling was used to describe the kinetics of the antibody response in seropositive and seronegative subjects, assuming a steady decay rate over time. The half-life was obtained from the one-compartment modeling which permitted the calculation of the elimination rate of the antibody response. Statistical analyses were performed using GraphPad Prism 9.0.1 (GraphPad Software) and

JMP Pro 16.0.0 (SAS Institute Inc., South Carolina, United States). P-value < 0.05 was considered significant.

Results

In this cohort, 77.5% (n = 155) were females (mean age = 43 years; range, 23-66 years) and 22.5% (n = 45) were males (mean age = 41 years; range, 24-64 years). One-hundred and forty-two persons (71%) were categorized as seronegative at baseline while 58 (29%) were seropositive (i.e. subjects having levels of anti-NCP and anti-S antibodies at baseline above the positivity cut-off). Anti-NCP antibodies remained stable in seropositive participants. In the seronegative group, no participant developed anti-NCP antibodies. None of the previously infected participants required hospitalization at the time of SARS-CoV-2 infection.

In seronegative individuals, the rate of seroconversion 14 days after the first dose was 95.7% (**Figure 1A**). From day 28 to day 90, all participants had detectable anti-S antibodies. The maximal antibody response was reached between days 28 and 42 (2,204 versus 1,863; P = 0.20), with a 48.8 to 57.7-fold increase compared to day 14 (i.e. 38.2 U/mL). Afterward, a continuous decrease was observed at days 56 (i.e. 1,517 U/mL) and 90 (i.e. 1,262 U/mL) (**Table 1, Figure 1A**). In seropositive individuals, the maximal antibody response was reached between days 14 and 42 (from 15,540 to 16,935; P >0.05), which represents a mean 122.1-fold increase compared to baseline (i.e. 132 U/mL). Afterward, a continuous decrease was observed at days 56 (i.e. 13,315 U/mL) and 90 (i.e. 8,919 U/mL) (**Table 1, Figure 1A**). All participants still had detectable anti-S antibodies up to day 90. Considering each time point separately, anti-S titers of seropositive individuals were always statistically higher compared to uninfected individuals (P < 0.0001) (**Table 1**). Importantly, the inter-individual variability was important in each group.

The estimated half-life of antibodies observed from data collected until 90 days post-vaccination for seronegative participants was 55 days (95% CI: 37-107 days) as calculated by the one-compartmental model. The time to maximum concentration was estimated at 36 ± 3 days. In seropositive participants, the estimated half-life of antibodies after 90 days was 80 days (95% CI, 46-303 days) and the time to maximum concentration was 24 ± 4 days (**Figure 1B**).

Discussion

In this study, we report a significant antibody decline 3 months post-vaccination in both seronegative and seropositive individuals who received two doses of the BNT162b2 vaccine. The highest mean antibody titer was observed between days 14 and 42 for seropositive participants and between 28 and 42 days for seronegative participants (**Table 1, Figure 1**). Based on the one-compartment model, the time to maximum concentration was estimated at 24 ± 4 days in seropositive versus 36 ± 3 days in

seronegative participants (**Figure 1B**). Previous studies also found an earlier maximal response in seropositive individuals.^{3,6}

At 3 months, a mean antibody decrease of 37.9% and 44.7% in seronegative and seropositive individuals was identified from the highest mean antibody response (**Table 1, Figure 1**). Nevertheless, it is important to notice that all participants still had a robust antibody response at 3 months. Moreover, the vaccination with BNT162b2 elicited much higher antibody titers at 3 months compared to the titers collected in serum from convalescent patients using the same assay (i.e. Roche Elecsys anti-S pan-Ig assay).^{7,8} Using the half-lives derived from the kinetics model, we could predict a drop below the positivity threshold (i.e. 0.8 U/mL for anti-S) after 554 days for seronegative and after 1,184 days for seropositive individuals. These predictions remains to date speculative and will need to be confirmed by subsequent sampling times but this could help to design vaccination strategies.⁹ The aim is to keep sufficient antibody levels to protect vaccinated subjects against wild-type SARS-CoV-2 but also the related variants, which have all demonstrated some forms of immunity escape.⁹ It has also been demonstrated that neutralizing antibodies better correlate with protection against infection than global serological testing and this may also serve in the future as a biomarker to ensure a proper protection at the patient's level.¹⁰ A limitation of this study included the lack of measurement of neutralizing capacity measurement. Data about the contribution of the cellular immune response are also missing.

Data about the long-term antibody kinetics in vaccinated subjects are still scarce. In a population of 33 healthy adults having received the Moderna mRNA-1273 vaccine and followed up to day 209, the estimated half-life was 52 days (95% CI: 46-58 days) using an exponential decay model.¹¹ In a cohort of 188 unvaccinated COVID-19 patients (mostly not hospitalized: 174/188) who were followed for up to 8 months, the antibody half-life was 83 days (95% CI: 62-126 days).¹² All these results were consistent with the results obtained in this study in both seronegative (i.e. 55 days, 95% CI: 37-107 days) and seropositive participants (i.e. 80 days, 95% CI: 46-303 days). Because the 95% CI are overlapping, we cannot conclude that half-lives are different between seropositive and seronegative participants. This study (EudraCT registration number: 2020-006149-21) has a planned follow-up of two years, with the next blood sampling campaign planned in July 2021. This will permit to further refine the kinetics model and to provide better estimate of the antibody response in both seropositive and seronegative individuals.

References


1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020;383:2603-15.
2. Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. *Nat Med* 2021.
3. Favresse J, Bayart JL, Mullier F, Dogne JM, Closset M, Douxfils J. Early antibody response in healthcare professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2). *Clin Microbiol Infect* 2021.
4. Padoan A, Dall'Olmo L, Rocca FD, et al. Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers. *Clinica chimica acta; international journal of clinical chemistry* 2021;519:60-3.
5. Tré-Hardy M, Cupaiolo R, Papeux E, et al. Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers. *J Infect* 2021.
6. Salvagno GL, Henry BM, di Piazza G, et al. Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination. *Diagnostics* 2021;11:832.
7. Favresse J, Eucher C, Elsen M, et al. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. *Microorganisms* 2021;9:556.
8. Schaffner A, Risch L, Aeschbacher S, et al. Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study. *J Clin Med* 2020;9.
9. Rubin R. COVID-19 Vaccines vs Variants—Determining How Much Immunity Is Enough. *JAMA* 2021;325:1241.
10. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature medicine* 2021.
11. Doria-Rose N, Suthar MS, Makowski M, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. *The New England journal of medicine* 2021.
12. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* 2021;371.

Table 1: Evolution of SARS-CoV-2 spike antibodies (U/mL) in seronegative and seropositive persons. Means with 95% confidence intervals are shown.

	Seronegative	Seropositive	P-value
Before first dose	0.40 (0.39-0.41)	132.0 (86.1-177.6)	<0.0001
14 days	38.2 (27.7-48.6)	15,540 (13,606-17,473)	<0.0001
28 days	2,204 (1,883-2,575)	16,935 (15,112-18,759)	<0.0001
42 days	1,863 (1,613-2,113)	15,896 (13,968-17,824)	<0.0001
56 days	1,517 (1,326-1,708)	13,315 (11,464-15,165)	<0.0001
90 days	1,262 (1,104-1,420)	8,919 (7,201-10,637)	<0.0001

Figure 1: Evolution of SARS-CoV-2 spike antibodies (U/mL) in seronegative (blue) and seropositive individuals (red) according to the time since the first vaccine dose administration. **(A)** Means with 95% confidence intervals are shown. An automatic dilution of 1/100 at >250 U/mL was performed by the analyzer to extend the measurement domain up to 25,000 U/mL. Forty-six samples were rounded to 25,000 U/mL out of 1,195 (3.8%). Results < 0.4 U/mL (limit of quantification) were rounded to 0.4. [§] = statistically different from all other groups (i.e. $P < 0.0001$). **(B)** Kinetic models of the humoral response based on a one-compartment model. A zoom of the seronegative population is presented in the right-upper part of the figure. Means with one standard deviation are shown.

(A)



(B)

